Children's oncology group's 2013 blueprint for research: Bone tumors

Richard Gorlick, Katherine Janeway, Stephen Lessnick, R Randall, Neyssa Marina

Research output: Contribution to journalReview article

82 Citations (Scopus)

Abstract

In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

Original languageEnglish (US)
Pages (from-to)1009-1015
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Osteosarcoma
Bone and Bones
Research
Neoplasms
Topotecan
Drug Therapy
Ifosfamide
Survival
Etoposide
Cyclophosphamide
Interferons
Neoplasm Metastasis
Pharmaceutical Preparations
Therapeutics

Keywords

  • Blueprint
  • Bone sarcoma
  • Ewing sarcoma
  • Osteosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Children's oncology group's 2013 blueprint for research : Bone tumors. / Gorlick, Richard; Janeway, Katherine; Lessnick, Stephen; Randall, R; Marina, Neyssa.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 01.06.2013, p. 1009-1015.

Research output: Contribution to journalReview article

Gorlick, Richard ; Janeway, Katherine ; Lessnick, Stephen ; Randall, R ; Marina, Neyssa. / Children's oncology group's 2013 blueprint for research : Bone tumors. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6. pp. 1009-1015.
@article{2eb9fb88105d48adb3b18a07e7e0d9f6,
title = "Children's oncology group's 2013 blueprint for research: Bone tumors",
abstract = "In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65{\%} to 75{\%} for localized disease and <30{\%} for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.",
keywords = "Blueprint, Bone sarcoma, Ewing sarcoma, Osteosarcoma",
author = "Richard Gorlick and Katherine Janeway and Stephen Lessnick and R Randall and Neyssa Marina",
year = "2013",
month = "6",
day = "1",
doi = "10.1002/pbc.24429",
language = "English (US)",
volume = "60",
pages = "1009--1015",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Children's oncology group's 2013 blueprint for research

T2 - Bone tumors

AU - Gorlick, Richard

AU - Janeway, Katherine

AU - Lessnick, Stephen

AU - Randall, R

AU - Marina, Neyssa

PY - 2013/6/1

Y1 - 2013/6/1

N2 - In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

AB - In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

KW - Blueprint

KW - Bone sarcoma

KW - Ewing sarcoma

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84876421334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876421334&partnerID=8YFLogxK

U2 - 10.1002/pbc.24429

DO - 10.1002/pbc.24429

M3 - Review article

C2 - 23255238

AN - SCOPUS:84876421334

VL - 60

SP - 1009

EP - 1015

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -